ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov. Counted 2026-11-10.

85,013 comparisons

Most participants first33,758 with no events in either group come last901 to 920 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
E-MOTIVE Intervention vs Usual Care: Number of Women Receiving Uterine Massage for PPH5,794 of 5,921

4,119 of 4,899

13.8 points

12.7 to 14.9

10,820NCT04341662

A Clinical Trial to Study the Effectiveness of a Care Bundle to Prevent Bleeding After a Woman Has Given Birth

ACP Educator Led, Video Assisted Discussion vs Usual Care: Identification of a Goals of Care Conversation in the Electronic Health Record (EHR) During the Index Hospitalization3,744 of 6,023

2,396 of 4,779

12.0 points

10.1 to 13.9

10,802NCT04857060

Palliative Care Educator

Intervention Arm vs Placebo Arm: Maternal Outcome 6 - Change in Maternal Hemoglobin290 of 5,393

333 of 5,398

-0.8 points

-1.7 to 0.1

10,791NCT02409680

Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)

LNG IUD vs Cu-IUD: Breast Cancer Risk1,076 of 5,346

1,068 of 5,428

0.5 points

-1.1 to 2.0

10,774NCT00461253

Case-Control-Study on the Breast Cancer Risk of Mirena® Compared With Copper IUDs

LNG IUD vs Cu-IUD: serious adverse events1,085 of 5,346

1,130 of 5,428

-0.5 points

-2.0 to 1.0

10,774NCT00461253

Case-Control-Study on the Breast Cancer Risk of Mirena® Compared With Copper IUDs

Open Group vs Masked Group: Number of Infants With Umbilical-artery Blood pH < = 7.05 and Base Deficit in Extracellular Fluid > = 12 mmol/Liter (Primary Outcome Component)3 of 5,362

8 of 5,359

-0.1 points

-0.2 to 0.0

10,721NCT01131260

Fetal ST Segment and T Wave Analysis in Labor

TICAGRELOR vs PLACEBO: Number of Participants With Modified Rankin Scale (mRS) Score >1 at Visit 31,282 of 5,386

1,284 of 5,333

-0.3 points

-1.9 to 1.3

10,719NCT03354429

THALES - Acute STroke or Transient IscHaemic Attack Treated With TicAgreLor and ASA for PrEvention of Stroke and Death

Intervention vs Control Group: Number of Patients Enrolled5,546 of 5,546

5,098 of 5,098

0.0 points

-0.1 to 0.1

10,644NCT03044158

GeneXpert Performance Evaluation for Linkage to Tuberculosis Care

Intervention vs Control Group: Number Diagnosed With Microbiologically-confirmed TB389 of 5,546

299 of 5,098

1.1 points

0.2 to 2.1

10,644NCT03044158

GeneXpert Performance Evaluation for Linkage to Tuberculosis Care

Intervention vs Control Group: Number Treated for TB485 of 5,546

339 of 5,098

2.1 points

1.1 to 3.1

10,644NCT03044158

GeneXpert Performance Evaluation for Linkage to Tuberculosis Care

Intervention vs Control Group: Number Treated for Microbiologically-confirmed TB Within 14 Days After Presentation to the Health Center for TB Evaluation342 of 5,546

220 of 5,098

1.9 points

1.0 to 2.7

10,644NCT03044158

GeneXpert Performance Evaluation for Linkage to Tuberculosis Care

Intervention vs Control Group: Number Diagnosed AND Treated for TB362 of 5,546

199 of 5,098

2.6 points

1.8 to 3.5

10,644NCT03044158

GeneXpert Performance Evaluation for Linkage to Tuberculosis Care

Intervention vs Control Group: Number Diagnosed and Treated for Microbiologically-confirmed TB251 of 5,546

106 of 5,098

2.4 points

1.8 to 3.1

10,644NCT03044158

GeneXpert Performance Evaluation for Linkage to Tuberculosis Care

Intervention vs Control Group: Number Tested for TB According to National Guidelines5,108 of 5,546

2,687 of 5,098

39.4 points

37.8 to 40.9

10,644NCT03044158

GeneXpert Performance Evaluation for Linkage to Tuberculosis Care

aQIV (≥6 to <72 Months) vs TIV/QIV (≥6 to <72 Months): deaths from any cause1 of 5,339

3 of 5,272

-0.0 points

-0.1 to 0.1

10,611NCT01964989

Clinical Study to Evaluate the Safety, Immunogenicity and Efficacy of Investigational Flu Vaccine Compared to Approved Flu Vaccine in Children.

Sotagliflozin vs Placebo: deaths from any cause246 of 5,292

246 of 5,292

0.0 points

-0.8 to 0.8

10,584NCT03315143

Effect of Sotagliflozin on Cardiovascular and Renal Events in Participants With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk

Sotagliflozin vs Placebo: serious adverse events1,236 of 5,291

1,331 of 5,286

-1.8 points

-3.5 to -0.2

10,577NCT03315143

Effect of Sotagliflozin on Cardiovascular and Renal Events in Participants With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk

Bococizumab (PF-04950615) vs Placebo: deaths from any cause54 of 5,276

61 of 5,279

-0.1 points

-0.5 to 0.3

10,555NCT01975389

The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects

Bococizumab (PF-04950615) vs Placebo: serious adverse events934 of 5,276

994 of 5,279

-1.1 points

-2.6 to 0.3

10,555NCT01975389

The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects

Pemafibrate vs Placebo: deaths from any cause308 of 5,264

310 of 5,274

-0.0 points

-0.9 to 0.9

10,538NCT03071692

Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT)

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=46

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT04341662-d92cacf0",
        "title": "E-MOTIVE Intervention vs Usual Care: Number of Women Receiving Uterine Massage for PPH",
        "summary": "5794 of 5921 against 4119 of 4899; risk difference 13.8 points, 95% interval 12.7 to 14.9; NCT04341662, A Clinical Trial to Study the Effectiveness of a Care Bundle to Prevent Bleeding After a Woman Has Given Birth",
        "record": "/library/comparisons/NCT04341662-d92cacf0",
        "nct_id": "NCT04341662",
        "kind": "outcome",
        "participants": 10820,
        "risk_difference": {
          "value": 0.13776708701723128,
          "lower": 0.12701271407868714,
          "upper": 0.1488126257845656
        },
        "group_1": "5,794 of 5,921",
        "group_2": "4,119 of 4,899",
        "difference": "13.8 points",
        "interval": "12.7 to 14.9",
        "trial_title": "A Clinical Trial to Study the Effectiveness of a Care Bundle to Prevent Bleeding After a Woman Has Given Birth"
      },
      {
        "id": "NCT04857060-7df5f7c5",
        "title": "ACP Educator Led, Video Assisted Discussion vs Usual Care: Identification of a Goals of Care Conversation in the Electronic Health Record (EHR) During the Index Hospitalization",
        "summary": "3744 of 6023 against 2396 of 4779; risk difference 12.0 points, 95% interval 10.1 to 13.9; NCT04857060, Palliative Care Educator",
        "record": "/library/comparisons/NCT04857060-7df5f7c5",
        "nct_id": "NCT04857060",
        "kind": "outcome",
        "participants": 10802,
        "risk_difference": {
          "value": 0.12025701713911974,
          "lower": 0.10147958126311983,
          "upper": 0.13893474100461248
        },
        "group_1": "3,744 of 6,023",
        "group_2": "2,396 of 4,779",
        "difference": "12.0 points",
        "interval": "10.1 to 13.9",
        "trial_title": "Palliative Care Educator"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "None stated"
    }
  ],
  "next": "/api/comparisons/v1?page=47",
  "request_id": "9rZHAFhO4wMj8qg_"
}
trial-comparisons-2026-03-23-0.1.0Next page

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNone stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Open193,990 genes2026-11-11

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Open611,552 trials2026-11-12

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

For invited accounts.

Opens sequences.conductscience.org

By invitation39,249,078 sequences2026-11-05

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?